180975-51-3

Usage

Uses

Used in Pharmaceutical Industry:
(cis)-5-Boc-Hexahydro-pyrrolo[3,4-b]pyrrole is used as an intermediate in the synthesis of Pyridoindole, a compound with potential applications in the treatment and prophylaxis of bacterial infections. Its unique structure allows for the development of new drugs that can target specific bacterial pathogens, offering a valuable contribution to the fight against antibiotic resistance.
Used in Organic Chemistry:
In the field of organic chemistry, (cis)-5-Boc-Hexahydro-pyrrolo[3,4-b]pyrrole serves as a versatile building block for the synthesis of more complex molecules. Its hexahydro-pyrrolo[3,4-b]pyrrole core can be further modified and functionalized to create a wide range of compounds with diverse properties and applications, making it a valuable tool for researchers in the field.

InChI:InChI=1/C11H20N2O2/c1-11(2,3)15-10(14)13-6-8-4-5-12-9(8)7-13/h8-9,12H,4-7H2,1-3H3/t8-,9+/m0/s1

Upstream product

• 370880-03-8 (3aR,6aR)-1-[(1R)-1-phenylethyl]-3,3a,4,5,6,6a-hexahydro-2H-pyrrolo[3,2-c]pyrrole 
• 24424-99-5 di-tert-butyl dicarbonate 
• 132414-80-3 tert-butyl 1-benzyl-octahydropyrrolo[2,3-c]pyrrole-5-carboxylate 
• 132414-50-7 1-benzyl-octahydropyrrolo[2,3-c]pyrrole 
• 132414-78-9 ethyl 1-benzyl-octahydropyrrolo[2,3-c]pyrrole-5-carboxylate 
• 34619-03-9 tert-butyldicarbonate 
• 128740-03-4 N-allyl-N-(2-oxoethyl)carbamic acid,ethyl ester 
• 128740-02-3 ethyl N-(2,2-dimethoxyethyl)-N-(prop-2-en-1-yl)carbamate 

Downstream Products

• 132414-59-6 cis-5-methyloctahydropyrrolo[2,3-c]pyrrole 
• 948846-79-5 (3aR,6aR)-5-methyl-1-(4-(4,4,5,5-tetramethyl-1,3-dioxaborolan-2-yl)-phenyl)-octahydro-pyrrolo[3,4-b]pyrrole 
• 948846-22-8 2-{5-[4-((3aR,6aR)-5-methyl-octahydro-pyrrolo[3,4-b]pyrrol-1-yl)-phenyl]-pyridin-2-yl}-2H-pyridazin-3-one 
• 948846-75-1 (3aR,6aR)-5-methyl-1-(4-piperazin-1-yl-phenyl)-octahydro-pyrrolo[3,4-b]pyrrole 

Relevant academic research and scientific papers

DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY

The disclosure provides compounds having formula (I), wherein the substituents are as defined herein. The compounds are useful for modulating the dopamine D3 receptor and for treating conditions associated therewith, such as addictions, drug dependency, and psychiatric conditions.

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

Modulators of chemokine receptor activity

Chemokine receptor antagonists, in particular, bicyclic diamine compounds of Formula (I) that act as antagonists of chemokine CCR2 and CCR3 receptors including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation are described herein.

PHENYLAMINOPYRIMIDINES AND THEIR USE AS RHO-KINASE INHIBITORS

The invention relates to the phenylaminopyrimidines of formula (I), wherein A, D, R1, R2, R3 and R4 are defined as in the description. The invention also relates to methods for producing said phenylaminopyrimidines and to their use for producing drugs for the treatment and/or the prophylaxis of diseases, especially cardiovascular diseases.

Diazabicyclic central nervous system active agents

Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.

7-(2,7-diazabicyclo[3.3.0]octyl)-3-quinoline- and -naphthyridone-carboxylic acid derivatives

The invention relates to new 7-(2,7-Diazabicyclo[3.3.0]octyl)-3-quinolone- and -naphthyridonecarboxylic acid derivatives, processes for their preparation, and antibacterial agents and feed additives containing them.

Preparation of 2,7-diazabicyclo[3.3.0]octanes

2,7-Diazabicyclo[3.3.0]octanes, suitable for 7-position substituents or antibacterially active quinolone carboxylic acids, of the formula STR1 in which R1, R3, R4, R5, R7 and R8 may be identical or different and in each case denote H, C1 -C5 -alkyl (optionally substituted by halogen, hydroxyl or C1 -C3 -alkoxy), C1 -C3 -alkoxycarbonyl or C6 -C12 -aryl, R4 additionally denotes halogen, R2 and R6 may be identical or different, denote H, C1 -C6 -alkyl, benzyl, C6 -C12 -aryl, C1 -C3 -alkanoyl, benzoyl or C1 -C5 -alkoxycarbonyl, or R2 and R3 together denote a bridge of the structure (CH2)n, n=2-4, CH2 --CHOH--CH2, CH2 --S--CH2 or C(CH3)2 --S--CH2, excluding 2,7-diazabicyclo[3.3.0]octane. Also their preparation by the reaction STR2 Intermediates II are also new.